Medscape is available in 5 Language Editions – Choose your Edition here.


Bacterial Conjunctivitis

  • Author: Karen K Yeung, OD, FAAO; Chief Editor: John D Sheppard, Jr, MD, MMSc  more...
Updated: Aug 10, 2016

Practice Essentials

Conjunctivitis, which is defined as inflammation of the bulbar and/or palpebral conjunctiva (the transparent lubricating mucous membrane that covers both the surface of the eye and lining of the undersurface of the eyelid), has many etiologies, including infection from various bacteria, fungi, and viruses, as well as toxic and allergic insults. Conjunctivitis is common; about 1% of all primary care office visits in the United States are related to conjunctivitis, affecting about 6 million people annually.[1, 2]

Only about 30% of primary care patients with infectious conjunctivitis are confirmed to have bacterial conjunctivitis, although 80% are treated with antibiotics.[3] The bacterial etiology often depends on geography and age, but the most common include Staphylococcus, Streptococcus, Corynebacterium, Haemophilus, Pseudomonas, and Moraxella species.

Complications can range from mild corneal irritation to severe visual loss, which develops in cases caused by extremely pathogenic bacteria, such as Chlamydia trachomatis or Neisseria gonorrhoeae. Bacterial conjunctivitis has been estimated to account for between $377 and $875 million annually in healthcare costs in the United States.[4]

Signs and symptoms

Signs and symptoms of bacterial conjunctivitis, beyond injected and edematous (inflamed) conjunctiva, include the following:

  • Follicles are a sign of ocular viral infections; may also occur with chronic allergic or hypersensitivity conjunctivitis
  • Papillae on the injected tarsal conjunctiva, also seen in viral conjunctivitis and ocular allergy (see below)
  • Discharge: More purulent than in viral conjunctivitis, with more mattering (generally white, green, or yellow mucous discharge) of the eyelid margins and greater associated difficulty prying the eyelids open following sleep; patients may report waking up with their eyes “glued” shut
  • Enlarged preauricular lymph node: Common in viral conjunctivitis and unusual in bacterial conjunctivitis, although found in severe bacterial conjunctivitis caused by N gonorrhoeae
  • Eyelid edema: Often present in bacterial conjunctivitis, but mild in most cases; severe eyelid edema in the presence of copious purulent discharge raises the suspicion of N gonorrhoeae infection

See Clinical Presentation for more detail.


Routine bacterial culture is indicated for specific cases of clinically suspected bacterial disease. These are best obtained with a commercially available sterile red-top culturette using applicators that contain artificial fiber, rather than cotton-tip applicators, which have bacteriostatic properties. Although most routine cases of bacterial conjunctivitis should not require culture confirmation, certain presentations, such as the following, suggest utility to the astute clinician:

  • Neonatal conjunctivitis
  • Hyperacute conjunctivitis suggestive of N gonorrhoeae
  • Extremely elderly patients
  • Nursing home patients
  • Immunocompromised patients: HIV infection, chemotherapy, immunosuppressive therapy
  • Recurrent or recalcitrant conjunctivitis
  • Corneal allograft recipients
  • Patients who have undergone recent intraocular surgery: pars plana vitrectomy, cataract, glaucoma shunt
  • Patients with a thinning or damaged trabeculectomy filtering bleb
  • Methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant Staphylococcus epidermidis (MRSE) carriers

Conjunctival scrapings are often used in the diagnosis of bacterial conjunctivitis; they can be collected with topical anesthetic and gentle use of a platinum spatula or similar blunt metallic object.

Gram stain is useful for identifying bacterial characteristics, including a rough bacterial titer, a rough estimate of white blood cell (WBC) count, and the presence of chains, clusters, and intracytoplasmic inclusions.

Giemsa stain is helpful in screening for intracellular inclusion bodies of Chlamydia.

Cultures can be completed for chlamydial and other bacterial organisms, as well as for viral agents. Fungal culture would be unusual except in the setting of a corneal ulcer, a vegetative or gardening injury, or in the case of known contamination of a contact lens solution. The cellular response in conjunctivitis differs according to the cause, as follows:

  • Bacterial infections: Neutrophils predominate
  • Viral infections: Lymphocytes predominate
  • Allergic reactions: Eosinophils predominate

See Workup for more detail.


The mainstay of treatment for bacterial conjunctivitis is topical (administered as eye drops or ointment) antibiotic therapy. Systemic antibiotics are indicated for gonorrhea and chlamydial infections. Under certain circumstances, topical antibiotics may be considered of limited benefit and, considering the risks of widespread antibiotic resistance, should be withheld while the disease course resolves without treatment.[5, 6, 7]

Steroid use is controversial (see Treatment for more details).

Povidone-iodine 1.25% ophthalmic solution may be a safe and viable alternative to topical antibiotics for treating bacterial conjunctivitis,[8] especially in resource-poor countries, where antibiotics may be scarce and/or expensive. A product that contains both povidone iodide 1% and dexamethasone 0.1% is in phase III clinical trials for the treatment of viral and bacterial conjunctivitis (Shire, Dublin, Ireland).



Conjunctivitis of the bulbar and/or palpebral conjunctiva can be caused by allergies, toxins, fungi, viruses, or bacteria.

Bacterial conjunctivitis due to gram-positive bacteria such as Staphylococcus aureus or Streptococcus pneumoniae is generally milder than conjunctivitis caused by gram-negative bacteria. Mild conjunctivitis is usually benign and self-limited and can be monitored without treatment or easily treated with antibiotics. Gram-negative conjunctivitis is caused by bacteria such as Pseudomonas, Serratia marcescens, Haemophilus influenzae, Moraxella, C trachomatis, and N gonorrhoeae. Gram-negative causes of conjunctivitis are especially virulent and can cause severe infections and possible ocular perforation within 24-48 hours of infection. Severe conjunctivitis can cause blindness and can signify a severe underlying systemic disease.

The purpose of this article is to (1) help the practitioner recognize the characteristics and significance of bacterial conjunctivitis, (2) avoid pitfalls in diagnosis, and (3) convey appropriate treatment modalities.

Conjunctival scrapings and cultures are commonly used to guide treatment choices and confirm the microbe in severe and bacterial conjunctivitis and that resistant to antibiotic treatment (see Workup). The mainstay of treatment of bacterial conjunctivitis is topical antibiotic therapy. Systemic antibiotics are indicated for N gonorrhoeae and chlamydial infections. Surgical intervention is required only if the cornea is involved and results in corneal opacification (see Treatment).

See the following for more information:

  • Acute Hemorrhagic Conjunctivitis
  • Allergic Conjunctivitis
  • Atopic Keratoconjunctivitis
  • Emergent Treatment of Acute Conjunctivitis
  • Epidemic Keratoconjunctivitis
  • Giant Papillary Conjunctivitis
  • Keratoconjunctivitis Sicca
  • Neonatal Conjunctivitis
  • Superior Limbic Keratoconjunctivitis
  • Viral Conjunctivitis


The surface tissues of the eye and the ocular adnexa are colonized by normal flora such as streptococci, staphylococci, and corynebacteria. Alterations in the host defense, in the bacterial titer, or in the species of bacteria can lead to clinical infection. Alteration in the flora can also result from external contamination (eg, contact lens wear, swimming), the use of topical or systemic antibiotics, or spread from adjacent infectious sites (eg, rubbing of the eyes).

The primary defense against infection is the epithelial layer covering the conjunctiva. Disruption of this barrier can lead to infection. Secondary defenses include hematologic immune mechanisms carried by the conjunctival vasculature; tear film immunoglobulins and lysozyme; and the rinsing action of lacrimation and blinking.



Bacterial conjunctivitis most often occurs in otherwise healthy individuals. Risk factors include exposure to infected individuals, fomite contact (eg, towels, napkins, pillow cases, slit-lamp chin rests and handles), contact lens wear, sinusitis, immunodeficiency states, prior ocular disease, trauma, and exposure to agents of sexually transmitted disease at birth.

Contact lens use is commonplace and thus deserves special consideration. It is known that contact lens wear, especially sleeping while wearing the lenses, is a common risk factor for bacterial corneal infection, especially in developed countries where contact lens use is more prevalent.[9] Risks for bacterial corneal infection in contact lens wearers are also known to increase with improperly maintaining contact lens integrity and contact lens case hygiene, improperly discarding the contact lenses, and exposing the contact lenses to water (eg, swimming, showering, tap water). Hence, treating presumed bacterial conjunctivitis in contact lens users, including discontinuing use of lenses and prescribing topical antibiotics, is usually prudent. However, allergic conjunctivitis in contact lens users is also common, and differentiation is important for treatment.



Bacterial conjunctivitis is common worldwide. The estimated incidence of bacterial conjunctivitis in the United States is 135 cases per 10,000 population annually,[4] constituting approximately 1% of all of all primary care consultations.[10] ​Internationally, isolated epidemics can be devastating in areas affected by blinding infections of newborns, especially in areas heavily affected by C trachomatis,[11] which can cause blindness in up to 8% of the population.[12] Staphylococcal infection was the most common etiology in Paraguay,[13] Pseudomonas in Thailand,[14] and streptococci in India.[15]

Racial and sexual differences in incidence

Bacterial conjunctivitis occurs in persons of all races, although differences in frequencies may be reflected by geographical variations of pathogen prevalence.

Males and females have equal natural resistance to bacterial conjunctivitis. Differences in infection rates may reflect environmental and behavioral patterns, such as the higher rate of contact lens use among women.

Age-related differences in incidence

Age is a relevant factor in the prevalence of bacterial conjunctivitis. In the United States, bacterial conjunctivitis is more prevalent in children than in adults; 23% of cases are reported in children aged 0-2 years, 28% in children aged 3-9 years, and 28% in children aged 10-19 years. Adults account for 36% of cases.[16] H influenzae is the most common pathogen in children, followed by S pneumoniae, S aureus, and Moraxella catarrhalis. In adults, S aureus, H influenzae, S pneumoniae, and Moraxella species are the most common pathogens; MRSA prevalence has been increasing in nursing homes.

The practitioner must be vigilant in considering sexually transmitted diseases caused by N gonorrhoeae and Chlamydia in sexually active age groups and in newborns who may have been exposed during birth. Tactful and confidential history taking are a necessary skill in order to avoid violating HIPAA regulations. In an ethical or medicolegal situation, obtaining advice from administration and/or colleagues is recommended.



The prognosis for complete recovery without sequelae is excellent in bacterial conjunctivitis, as long as the cornea is not involved. Most benign cases are treated with topical antibiotics or self-resolve.[17] Bacterial conjunctivitis generally resolves within 1-2 weeks. Complications are expected to develop only in cases caused by extremely pathogenic bacteria, such as C trachomatis or N gonorrhoeae.

Mortality in the setting of bacterial conjunctivitis is related to the failure to recognize and treat the underlying disease. Sepsis and meningitis caused by N gonorrhoeae can be life-threatening.[18] Chlamydial infection in the newborn can lead to pneumonia and/or otitis media.[19]

Signs and symptoms of discomfort, mucopurulent ocular discharge, and conjunctival redness are common in benign cases and often lead to absence from work and school to minimize infection to others. Morbidity can be associated with misdiagnosis. Since many eye diseases cause the eye to be red, it is beneficial to have a solid clinical approach to differential diagnoses of the red eye, as well as an effective referral paradigm in the primary care setting. Diagnoses often missed by non–eye-care providers (ophthalmologists and optometrists) include acute glaucoma; iritis; bacterial, fungal, and parasitic keratitis; corneal foreign bodies; conjunctival and tarsal foreign bodies; herpetic dendritic keratitis; scleritis; and subconjunctival hemorrhage, among others.


Patient Education

To prevent bacterial conjunctivitis, patient education should include good hygiene (eg, washing hands with soap and water) and avoidance of touching the eyes, especially after exposure to potentially infectious people. Proper contact lens care includes avoidance of contact lenses wear while sleeping and proper cleaning and discarding of the lenses and contact lens cases.

Patients with bacterial conjunctivitis should be instructed not to touch their eyes and to avoid sharing fomites. They should also be educated regarding their infectious nature to prevent transmission and the importance of finishing their antibiotic regimen. Patients with bacterial conjunctivitis who wear contact lenses should be instructed to discontinue contact lens use and to discard their used contact lenses, open contact lens solutions, used contact lens cases, and used makeup and makeup brushes.

Contributor Information and Disclosures

Karen K Yeung, OD, FAAO Senior Optometrist, Arthur Ashe Student Health and Wellness Center, University of California, Los Angeles

Karen K Yeung, OD, FAAO is a member of the following medical societies: American Academy of Optometry

Disclosure: Nothing to disclose.


Barry A Weissman, OD, PhD, FAAO Professor of Optometry, Southern California College of Optometry; Professor Emeritus of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Barry A Weissman, OD, PhD, FAAO is a member of the following medical societies: American Academy of Optometry, American Optometric Association, California Optometric Society, International Society for Contact Lens Research

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

John D Sheppard, Jr, MD, MMSc Professor of Ophthalmology, Microbiology and Molecular Biology, Clinical Director, Thomas R Lee Center for Ocular Pharmacology, Ophthalmology Residency Research Program Director, Eastern Virginia Medical School; President, Virginia Eye Consultants

John D Sheppard, Jr, MD, MMSc is a member of the following medical societies: American Academy of Ophthalmology, American Society for Microbiology, American Society of Cataract and Refractive Surgery, Association for Research in Vision and Ophthalmology, American Uveitis Society

Disclosure: Nothing to disclose.

Additional Contributors

Maria Elena De Shazer University of California at Los Angeles

Disclosure: Nothing to disclose.


Jerre Freeman, MD Founder, Chairman, Memphis Eye and Cataract Associates; Clinical Professor, Department of Ophthalmology, University of Tennessee Health Science Center College of Medicine

Jerre Freeman, MD is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, American Society of Cataract and Refractive Surgery, and Tennessee Medical Association

Disclosure: Nothing to disclose.

Simon K Law, MD, PharmD Associate Professor of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology

Disclosure: Nothing to disclose.

Christopher J Rapuano, MD Professor, Department of Ophthalmology, Jefferson Medical College of Thomas Jefferson University; Director of the Cornea Service, Co-Director of Refractive Surgery Department, Wills Eye Institute

Christopher J Rapuano, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, Cornea Society, Eye Bank Association of America, International Society of Refractive Surgery, and Pan-American Association of Ophthalmology

Disclosure: Allergan Honoraria Speaking and teaching; Allergan Consulting fee Consulting; Alcon Honoraria Speaking and teaching; Inspire Honoraria Speaking and teaching; RPS Ownership interest Other; Vistakon Honoraria Speaking and teaching; EyeGate Pharma Consulting; Inspire Consulting fee Consulting; Bausch & Lomb Honoraria Speaking and teaching; Bausch & Lomb Consulting fee Consulting

  1. Shields T, Sloane PD. A comparison of eye problems in primary care and ophthalmology practices. Fam Med. 1991 Sep-Oct. 23 (7):544-6. [Medline].

  2. Udeh BL, Schneider JE, Ohsfeldt RL. Cost effectiveness of a point-of-care test for adenoviral conjunctivitis. Am J Med Sci. 2008 Sep. 336 (3):254-64. [Medline].

  3. van Weert HC, Tellegen E, Ter Riet G. A new diagnostic index for bacterial conjunctivitis in primary care. A re-derivation study. Eur J Gen Pract. 2014 Sep. 20 (3):202-8. [Medline].

  4. Smith AF, Waycaster C. Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States. BMC Ophthalmol. 2009 Nov 25. 9:13. [Medline].

  5. Narayana S, McGee S. Bedside Diagnosis of the 'Red Eye': A Systematic Review. Am J Med. 2015 Nov. 128 (11):1220-1224.e1. [Medline].

  6. Jefferis J, Perera R, Everitt H, van Weert H, Rietveld R, Glasziou P, et al. Acute infective conjunctivitis in primary care: who needs antibiotics? An individual patient data meta-analysis. Br J Gen Pract. 2011 Sep. 61 (590):e542-8. [Medline].

  7. Rietveld RP, ter Riet G, Bindels PJ, Schellevis FG, van Weert HC. Do general practitioners adhere to the guideline on infectious conjunctivitis? Results of the Second Dutch National Survey of General Practice. BMC Fam Pract. 2007 Sep 16. 8:54. [Medline].

  8. Isenberg SJ, Apt L, Valenton M, Del Signore M, Cubillan L, Labrador MA. A controlled trial of povidone-iodine to treat infectious conjunctivitis in children. Am J Ophthalmol. 2002 Nov. 134(5):681-8. [Medline].

  9. Jeng BH, Gritz DC, Kumar AB, Holsclaw DS, Porco TC, Smith SD, et al. Epidemiology of ulcerative keratitis in Northern California. Arch Ophthalmol. 2010 Aug. 128 (8):1022-8. [Medline].

  10. Høvding G. Acute bacterial conjunctivitis. Acta Ophthalmol. 2008 Feb. 86 (1):5-17. [Medline].

  11. Rapoza PA, Quinn TC, Kiessling LA, Taylor HR. Epidemiology of neonatal conjunctivitis. Ophthalmology. 1986 Apr. 93(4):456-61. [Medline].

  12. Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, et al. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health. 2013 Dec. 1 (6):e339-49. [Medline].

  13. Laspina F, Samudio M, Cibils D, Ta CN, Fariña N, Sanabria R, et al. Epidemiological characteristics of microbiological results on patients with infectious corneal ulcers: a 13-year survey in Paraguay. Graefes Arch Clin Exp Ophthalmol. 2004 Mar. 242 (3):204-9. [Medline].

  14. Sirikul T, Prabriputaloong T, Smathivat A, Chuck RS, Vongthongsri A. Predisposing factors and etiologic diagnosis of ulcerative keratitis. Cornea. 2008 Apr. 27 (3):283-7. [Medline].

  15. Leck AK, Thomas PA, Hagan M, Kaliamurthy J, Ackuaku E, John M, et al. Aetiology of suppurative corneal ulcers in Ghana and south India, and epidemiology of fungal keratitis. Br J Ophthalmol. 2002 Nov. 86 (11):1211-5. [Medline].

  16. Lichtenstein SJ, Rinehart M, Levofloxacin Bacterial Conjunctivitis Study Group. Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients. J AAPOS. 2003 Oct. 7 (5):317-24. [Medline].

  17. Sheikh A, Hurwitz B, van Schayck CP, McLean S, Nurmatov U. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2012 Sep 12. 9:CD001211. [Medline].

  18. Ullman S, Roussel TJ, Culbertson WW, Forster RK, Alfonso E, Mendelsohn AD, et al. Neisseria gonorrhoeae keratoconjunctivitis. Ophthalmology. 1987 May. 94(5):525-31. [Medline].

  19. Schachter J, Lum L, Gooding CA, Ostler B. Pneumonitis following inclusion blennorrhea. J Pediatr. 1975 Nov. 87(5):779-80. [Medline].

  20. Horner C, Wilcox M, Barr B, Hall D, Hodgson G, Parnell P, et al. The longitudinal prevalence of MRSA in care home residents and the effectiveness of improving infection prevention knowledge and practice on colonisation using a stepped wedge study design. BMJ Open. 2012. 2 (1):e000423. [Medline].

  21. Rietveld RP, ter Riet G, Bindels PJ, Sloos JH, van Weert HC. Predicting bacterial cause in infectious conjunctivitis: cohort study on informativeness of combinations of signs and symptoms. BMJ. 2004 Jul 24. 329 (7459):206-10. [Medline].

  22. Alfonso EC, Cantu-Dibildox J, Munir WM, Miller D, O'Brien TP, Karp CL, et al. Insurgence of Fusarium keratitis associated with contact lens wear. Arch Ophthalmol. 2006 Jul. 124 (7):941-7. [Medline].

  23. Borkar DS, Acharya NR, Leong C, Lalitha P, Srinivasan M, Oldenburg CE, et al. Cytotoxic clinical isolates of Pseudomonas aeruginosa identified during the Steroids for Corneal Ulcers Trial show elevated resistance to fluoroquinolones. BMC Ophthalmol. 2014 Apr 24. 14:54. [Medline].

  24. Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, O'Brien KS, et al. The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial. Am J Ophthalmol. 2014 Feb. 157 (2):327-333.e3. [Medline].

  25. Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, Ray KJ, et al. Visual recovery in treated bacterial keratitis. Ophthalmology. 2014 Jun. 121 (6):1310-1. [Medline].

  26. Hammerschlag MR, Cummings C, Roblin PM, Williams TH, Delke I. Efficacy of neonatal ocular prophylaxis for the prevention of chlamydial and gonococcal conjunctivitis. N Engl J Med. 1989 Mar 23. 320(12):769-72. [Medline].

  27. [Guideline] AAO Cornea/External Disease PPP Panel, Hoskins Center for Quality Eye Care. Conjunctivitis PPP. ONE Network. Available at 2013;

  28. Sheikh A, Hurwitz B, van Schayck CP, McLean S, Nurmatov U. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2012 Sep 12. 9:CD001211. [Medline].

  29. Asbell PA, Colby KA, Deng S, McDonnell P, Meisler DM, Raizman MB, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol. 2008 Jun. 145 (6):951-958. [Medline].

  30. Asbell PA, Sanfilippo CM, Pillar CM, DeCory HH, Sahm DF, Morris TW. Antibiotic Resistance Among Ocular Pathogens in the United States: Five-Year Results From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study. JAMA Ophthalmol. 2015 Dec. 133 (12):1445-54. [Medline].

  31. O'Brien TP. Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis. Adv Ther. 2012 Jun. 29(6):473-90. [Medline].

  32. Aoki R, Fukuda K, Ogawa M, Ikeno T, Kondo H, Tawara A, et al. Identification of Causative Pathogens in Eyes with Bacterial Conjunctivitis by Bacterial Cell Count and Microbiota Analysis. Ophthalmology. 2012 Dec 12. [Medline].

  33. Tabbara KF, Hyndiuk RA. Infections of the Eye. Boston, Mass: Little, Brown and Company; 1996.

  34. Deschênes J, Blondeau J. Besifloxacin in the management of bacterial infections of the ocular surface. Can J Ophthalmol. 2015 Jun. 50 (3):184-91. [Medline].

  35. Kitatani F, Fujimoto S, Asahi T, Konishiike J, Sera Y. [Clinical study on rifampicin applied every other day for severe cavitary pulmonary tuberculosis (author's transl)]. Kekkaku. 1974 May. 49 (5):133-8. [Medline].

  36. Deschênes J, Blondeau J. Besifloxacin in the management of bacterial infections of the ocular surface. Can J Ophthalmol. 2015 Jun. 50 (3):184-91. [Medline].

  37. Garnock-Jones KP. Azithromycin 1.5% ophthalmic solution: in purulent bacterial or trachomatous conjunctivitis. Drugs. 2012 Feb 12. 72 (3):361-73. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.